Sugi Predict

Sugi Predict / Compounds / SCHEMBL29532946

SCHEMBL29532946

SCHEMBL29532946

CC(=O)N[C@H]1[C@H](O[C@@H]2[C@H](O[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O3)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)O[C@H](CO)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.70

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SELP P16109 2/20 0.67
▸ SELL P14151 1/20 0.67
▸ SIGLEC7 Q9Y286 6/20 0.66
▸ MAG P20916 7/20 0.64
▸ SELE P16581 4/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30653953 1.00 SELP (0.67) SELPSELLSIGLEC7MAGSELE
SCHEMBL31701003 0.98 SELP (0.64) SELPSELLSIGLEC7MAGSELE
SCHEMBL31700826 0.98 SELP (0.64) SELPSELLSIGLEC7MAGSELE
SCHEMBL30653352 0.98 MAG (0.66) SELPSELLSIGLEC7MAGSELE
SCHEMBL31701590 0.98 MAG (0.66) SELPSELLSIGLEC7MAGSELE
SCHEMBL30653577 0.98 SELP (0.69) SELPSELLSIGLEC7MAGSELE
SCHEMBL31701547 0.97 MAG (0.66) SELPSELLSIGLEC7MAGSELE
SCHEMBL29615736 0.97 SIGLEC7 (0.67) SELPSELLSIGLEC7MAGSELE
SCHEMBL18653452 0.97 SIGLEC7 (0.67) SELPSELLSIGLEC7MAGSELE
SCHEMBL31700633 0.97 SIGLEC7 (0.71) SELPSELLSIGLEC7MAGSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS INC (US) 2025-10-16 — — US disclosed
US-20250242035-A1 GLYCAN CONJUGATE COMPOSITIONS AND METHODS GANNA BIO, INC. 2025-07-31 — — US disclosed
WO-2025064617-A2 LIPOSOMAL FORMULATIONS FOR TREATMENT OF GM1 DEFICIENCIES SENEB BIOSCIENCES, INC. (US) 2025-03-27 — — WO disclosed
EP-4522646-A2 APOE LIPOPROTEIN SYSTEMS Kisbee Therapeutics, Inc. (US) 2025-03-19 — — EP disclosed
WO-2025049634-A1 GLYCAN CONJUGATE COMPOSITIONS AND METHODS GANNA BIO, INC. (US) 2025-03-06 — — WO disclosed
EP-4514812-A1 TREATMENT OF GM1 DEFICIENCIES Seneb Biosciences, Inc. (US) 2025-03-05 — — EP disclosed
WO-2023220387-A2 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS, INC. (US) 2023-11-16 — — WO disclosed
WO-2023212741-A1 TREATMENT OF GM1 DEFICIENCIES SENEB BIOSCIENCES, INC. (US) 2023-11-02 — — WO disclosed
US-11390680-B2 Anti-Siglec-7 antibodies and methods of use thereof ALECTOR LLC (US) 2022-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS APOB, APOL1, LDLR SELP 158/4885SELL 156/4885SIGLEC7 692/4885
US-20250242035-A1 GLYCAN CONJUGATE COMPOSITIONS AND METHODS SIGLEC7, SIGLEC9, ENGASE SELP 128/4885SELL 220/4885SIGLEC7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback